Biochemical studies of a new antitumor agent, O2,2'-cyclocytidine.
D000812:Anhydrides / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000378:metabolism; D001854:Bone Marrow Cells; D002250:Carbon Radioisotopes; D002460:Cell Line; D002478:Cells, Cultured; D003561:Cytarabine / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000378:metabolism; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006801:Humans; D006868:Hydrolysis; D007939:Leukemia L1210 / Q000378:metabolism; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014184:Transplantation, Homologous; D014316:Tritium; D014529:Uridine / Q000378:metabolism; D014633:Valine / Q000378:metabolism
D000812:Anhydrides; D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D003561:Cytarabine; D014316:Tritium; D014633:Valine; D013936:Thymidine; D014529:Uridine